Theracryf PLC (TCF)

ORD 0.25P

Sell: 0.20p|Buy: 0.22p|Change: 0.01 (-2.38%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

0.21p

Previous close

0.21p

Trade high

0.22p

Volume

1,420,034

Year high

1.25p

Year low

0.175p

Dividend yield

–

Market capitalisation

£4.41 mn

P/E ratio

–

ISIN

GB00BSVYN304

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 15/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Theracryf PLC	- 4.55
FTSE AIM All Share	- 0.27
More...

Company profile

TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
16/10/2025	02:49:33	0.205	600,000	1,230.00
16/10/2025	02:00:04	0.22	100,000	220.00
16/10/2025	11:31:57	0.205	72,600	148.83
16/10/2025	10:38:14	0.202	45,500	91.91
16/10/2025	09:15:04	0.216	34,666	74.88

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.